Galy G, Labidi S I, Tissier F, Combes J-D, Auger A, Favier B, Latour J-F
Pharmacie, centre Léon-Bérard, 28 rue Laennec, 69008 Lyon, France.
Bull Cancer. 2009 Feb;96(2):141-5. doi: 10.1684/bdc.2008.0819.
Aprepitant is actually recommended in the prevention of nausea and vomiting induced by high emetic risk chemotherapy using cisplatin. We performed an observational prospective study on 101 patients evaluating the efficacy of aprepitant in the clinical conditions of use of cisplatin, out of context of clinical trial. We did not perform any intervention on the choice of anti-emetic treatment by the clinicians. Data on anti-emetic treatments were collected from prescriptions by a pharmacist after prior consultation with a medical doctor. Inclusions were closed when we lay 50 patients who received aprepitant associated to standard anti-emetic treatment (ondansetron and prednisolone) and 51 patients who received standard anti-emetic treatment. We observed a significant positive effect of aprepitant in the prevention of acute (84 vs 74.4 %, P = 0.24) and delayed vomiting (84 vs 60.8%, P = 0.009). But there was not a significant difference between the two groups regarding the prevention of nausea and the rate of complete response (absence of nausea and vomiting during five days).
阿瑞匹坦实际上被推荐用于预防使用顺铂的高致吐风险化疗所引起的恶心和呕吐。我们对101名患者进行了一项观察性前瞻性研究，在临床试验背景之外评估阿瑞匹坦在顺铂临床使用情况下的疗效。我们没有对临床医生选择止吐治疗进行任何干预。止吐治疗的数据是在与医生事先协商后由药剂师从处方中收集的。当我们纳入50名接受阿瑞匹坦联合标准止吐治疗（昂丹司琼和泼尼松龙）的患者和51名接受标准止吐治疗的患者后，入组结束。我们观察到阿瑞匹坦在预防急性呕吐（84%对74.4%，P = 0.24）和延迟性呕吐（84%对60.8%，P = 0.009）方面有显著的积极效果。但两组在预防恶心和完全缓解率（五天内无恶心和呕吐）方面没有显著差异。
